A Dose Adjusted, Open Label, Multi-Center Study to Determine the Safety, Tolerability and Pharmacokinetics of STC3141 Administered as an Infusion for up to 72 hours in Subjects with Sepsis and Normal or Compromised Renal Function in an Intensive Care Unit (REFINE)

  • Udy, Andrew (Primary Chief Investigator (PCI))
  • Young, Meredith (Project Manager)

Project: Research

Project Details

Effective start/end date19/02/2131/12/22


  • Intensive care research
  • Sepsis
  • Clinical trial